Background: Currently, there is an extensive but highly inconsistent body of literature regarding donor adverse events (AEs) in haemapheresis. As the reports diverge with respect to types and grading of AEs, apheresis procedures and machines, the range of haemapheresis-related AEs varies widely from about 0.03% to 6.6%. Methods: The German Society for Transfusion Medicine and Immunohaematology (DGTI) formed a ‘Haemapheresis Vigilance Working Party' (Arbeitsgemeinschaft Hämapheresevigilanz; AGHV) to create an on-line registry for comprehensive and comparable AE assessment with all available apheresis devices in all types of preparative haemapheresis: plasmapheresis (PLS), plateletpheresis (PLT), red blood cell apheresis, all kind of leukaphereses (autologous/allogeneic blood stem cell apheresis, granulocyte apheresis, lymphocyte/monocyte apheresis) and all possible types of multi-component apheresis. To ensure the comparability of the data, the AGHV adopted the ‘Standard for Surveillance of Complications Related to Blood Donation' from the International Society for Blood Transfusion in cooperation with the International Haemovigilance Network (IHN) and the American Association of Blood Banks for AE acquisition and automated evaluation. The registry is embedded in a prospective observational multi-centre study with a study period of 7 years. Results: A preliminary evaluation encompassed the time period from January, 2012 to December, 2015. During this time, the system proved to be safe and stable. Out of approximately 345,000 haemaphereses 16,477 AEs were reported (4.9%) from 20 participating centres. The majority of AEs occurred in PLSs (63%), followed by PLT (34.5%) and SC (2.2%). Blood access injuries (BAI) accounted for about 55% of the supplied AEs, whereas citrate toxicity symptoms, vasovagal reactions and technical events (e.g. disposable leakages, software failures) rather equally affected haemaphereses at 8-15%. Out of 12,348 finalized AEs, 8,759 (70.1%) were associated with a procedure-related break-off, with BAI being the prevailing cause (5,463/8,759; 62.4%). An automated centre- and procedure-specific AE evaluation according to the latest IHN standard and AGHV pre-settings is available within a few minutes. Conclusions: An on-line electronic platform for comprehensive assessment and centre-specific automated evaluation of AEs in haemaphereses has been developed and proved to be stable and safe over a period of 4 years.

Keywords:
Adverse reactions, Haemapheresis, Haemovigilance, Plasmapheresis, Plateletpheresis, Stem cell collection, Donor safety, Adverse events
1.
Heuft HG, Moog R, Fischer EG, Zingsem J; German and Austrian Plateletpheresis Study Group: Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial. Transfusion 2013;53:211-220.
2.
Thorausch K, Schulz M, Bialleck H, Luxembourg B, Seifried E, Bonig H: Granulocyte collections: comparison of two apheresis systems. Transfusion 2013;53:3262-3268.
3.
Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H: Allogeneic donor peripheral blood stem cell apheresis: prospective comparison of two apheresis systems. Transfusion 2012;52:1137-1145.
4.
Heuft H-G, Goudeva L, Martens J, Krettek U, Priesner C, Aleksandrova K, Blasczyk R: T-cell collections from healthy donors for therapeutic use. Transfus Med Hemother 2015:42(suppl 1):54 (abstract).
5.
Picker SM, Radojska SM, Gathof BS: Evaluation of concurrent collection of in-line filtered platelets and packed red blood cells by multicomponent apheresis with three last-generation apparatuses. Vox Sang 2006;91:47-55.
6.
Report to the Withdrawal, Production, Importation, Exportation and Therapeutic Application of Blood Components according §21 German Transfusion Law (in German). www.pei.de/DE/infos/meldepflichtige/ meldung-blutprodukte-21-transfusionsgesetz/berichte/ berichte-21tfg-node.html (last accessed October 26, 2016).
7.
Tullis JL: Separation and purification of leucocytes and platelets. Blood 1952;7:891-896.
8.
Maurício R, de Sousa G, Seghatchian J: What's happening: an overview of potential adverse reactions associated with apheresis technology. Transfus Apher Sci 2005;33:351-356.
9.
Danic B, Lefort C: Serious adverse effects of blood collection (in French). Transfus Clin Biol 2010;17:301-305.
10.
Eder AF, Dy BA, Kennedy JM, Notari Iv EP, Strupp A, Wissel ME, Reddy R, Gibble J, Haimowitz MD, Newman BH, Chambers LA, Hillyer CD, Benjamin RJ: The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008;48:1809-1819.
11.
Diekamp U, Gneißl J, Rabe A, Kießig ST: Donor hemovigilance during preparatory plasmapheresis. Transfus Med Hemother 2014;41:123-133.
12.
McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW: Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998;38:938-943.
13.
Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E: Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999;77:24-32.
14.
Yuan S, Gornbein J, Smeltzer B, Ziman AF, Lu Q, Goldfinger D: Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections. Transfusion 2008;48:1213-1219.
15.
Yuan S, Ziman A, Smeltzer B, Lu Q, Goldfinger D: Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion 2010;50:478-486.
16.
Wiltbank TB, Giordano GF: The safety profile of automated collections: an analysis of more than 1 million collections. Transfusion 2007;47:1002-1005.
17.
Ounnoughene N, Sandid I, Carlier M, Joussemet M, Ferry N: The blood donors' haemovigilance in France (in French). Transfus Clin Biol 2013;20:182-192.
18.
Bueno JL, Castro E, García F, Barea L, González R: Hematomas in multicomponent apheresis: searching for related factors. Transfusion 2006;46:2184-2191.
19.
Tomita T, Takayanagi M, Kiwada K, Mieda A, Takahashi C, Hata T: Vasovagal reactions in apheresis donors. Transfusion 2002;42:1561-1566.
20.
Kamel H, Tomasulo P, Bravo M, Wiltbank T, Cusick R, James RC, Custer B: Delayed adverse reactions to blood donation. Transfusion 2010;50:556-565.
21.
Crocco I, Franchini M, Garozzo G, Gandini AR, Gandini G, Bonomo P, Aprili G: Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus 2009;7:35-38.
22.
Rosencher J, Zuily S, Varenne O, Spaulding C, Weber S: Acute myocardial infarction secondary to platelet apheresis in a 57-year healthy donor. Int J Cardiol 2011;150:119-120.
23.
Song EY, Yoon JH, Lee JW, Park CW, Kwon SW, Kim DW, Lim YA, Kim HO, Han KS: Establishment of a national on-line registry for apheresis in Korea. Transfus Apher Sci 2008;38:93-100.
24.
Working Group on Donor Vigilance: Standard for Surveillance of Complications Related to Blood Donation. Released in December 2014 by the International Society of Blood Transfusion (ISBT) in cooperation with the International Haemovigilance Network and the American Association of Blood Banks. www.isbtweb.org/fileadmin/user_upload/2_Donor-Standard-Definitions.pdf (last accessed October 26, 2016).
25.
Richtlinie 2002/98/EG des europäischen Parlaments und des Rates vom 27. Januar 2003 zur Festlegung von Qualitäts- und Sicherheitsstandards für die Gewinnung, Testung, Verarbeitung, Lagerung und Verteilung von menschlichem Blut und Blutbestandteilen und zur Änderung der Richtlinie 2001/83/EG. Veröffentlicht im Amtsblatt der europäischen Union vom 08.02.2003
26.
Gesetz über den Verkehr mit Arzneimitteln. www. gesetze-im-internet.de/amg_1976/__63i.html (last accessed October 26, 2016).
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.